HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chen-Yen Lin Selected Research

ixekizumab

5/2022Disease response and patient-reported outcomes among initiators of ixekizumab.
3/2021Rapid and sustained improvements in patient-reported signs and symptoms with ixekizumab in biologic-naive and TNF-inadequate responder patients with psoriatic arthritis.
2/2021Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis.
1/2021Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies.
1/2021Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors.
11/2020Clinically meaningful improvement in work productivity loss in active psoriatic arthritis: post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 trials.
8/2020Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis.
6/2020Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.
4/2020Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
2/2020Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Chen-Yen Lin Research Topics

Disease

14Psoriasis (Pustulosis Palmaris et Plantaris)
05/2022 - 12/2016
8Psoriatic Arthritis
03/2021 - 01/2017
3Pain (Aches)
03/2021 - 11/2013
3Prostatic Neoplasms (Prostate Cancer)
03/2014 - 11/2013
2Neoplasms (Cancer)
01/2019 - 03/2017
1Arthralgia (Joint Pain)
03/2021
1Fatigue
03/2021
1Rheumatic Diseases (Rheumatism)
01/2021
1Atopic Dermatitis (Atopic Eczema)
09/2020
1Necrosis
07/2019
1Ankylosing Spondylitis
07/2019
1Glioma (Gliomas)
01/2019
1Rheumatoid Arthritis
12/2017
1Dementia (Dementias)
08/2017

Drug/Important Bio-Agent (IBA)

19ixekizumabIBA
05/2022 - 12/2016
5Biological ProductsIBA
03/2021 - 01/2017
4Adalimumab (Humira)FDA Link
11/2020 - 01/2017
4Interleukin-17 (Interleukin 17)IBA
06/2020 - 01/2017
3Etanercept (Enbrel)FDA Link
08/2020 - 12/2016
2Immunoglobulin A (IgA)IBA
05/2022 - 09/2020
2ametantrone (HAQ)IBA
03/2021 - 01/2021
2Tumor Necrosis Factor InhibitorsIBA
03/2021 - 01/2021
2Monoclonal AntibodiesIBA
06/2020 - 01/2017
2secukinumabIBA
04/2020 - 12/2019
2Prostate-Specific Antigen (Semenogelase)IBA
11/2013 - 11/2013
2Docetaxel (Taxotere)FDA Link
11/2013 - 11/2013
1Methotrexate (Mexate)FDA LinkGeneric
01/2021
1Pharmaceutical PreparationsIBA
09/2020
1Indicators and Reagents (Reagents)IBA
08/2020
1Thioridazine (Mellaril)FDA LinkGeneric
01/2019
1CateninsIBA
01/2019
1phenothiazineIBA
01/2019
1Antipsychotic Agents (Antipsychotics)IBA
01/2019
1baricitinibIBA
12/2017
1LDL Lipoproteins (beta Lipoproteins)IBA
08/2017
1oxidized low density lipoproteinIBA
08/2017
1A-factor (Streptomyces)IBA
08/2017
1Adrenal Cortex Hormones (Corticosteroids)IBA
03/2017
1Antirheumatic Agents (DMARD)IBA
01/2017
1Hemoglobins (Hemoglobin)IBA
11/2013
1Alkaline PhosphataseIBA
11/2013

Therapy/Procedure

3Castration
03/2014 - 11/2013
3Drug Therapy (Chemotherapy)
03/2014 - 11/2013
2Aftercare (After-Treatment)
08/2020 - 12/2016
1Therapeutics
01/2018
1Phototherapy (Light Therapy)
03/2017